Pro-inflammatory pathways, including apoptosis signaling kinase-1 (ASK-1)-JNK, MAP kinases, extracellular signal-regulated kinase, and Nuclear Factor-kappa B, are potent mediators of inflammation and thus potential targets for MASLD therapy
Ros control over the entire supply chain, from diagnosis to delivery, creates physical and logistical barriers to entry that are much more difficult and expensive to replicate
GLP-1 agonists have the added benefit of inducing weight loss
In 2015, a landmark trial published the New England Journal of Medicine showed that a once daily subcutaneous injection of liraglutide produced a more than 10 per cent weight loss in a third of those living with obesity and without type 2 diabetes
showed that the MCT inhibitor syrosingopine reduced Treg cell numbers while increasing NK cells and M1-type TAMs, indicating a reversal of the immunosuppressive TME [370]